The Avandia (rosiglitazone) debate will heat up again

The Avandia (rosiglitazone) debate will heat up again...due to loosening of prescribing restrictions in the U.S.

This decision is based on a reanalysis of an older study that suggests Avandia DOES NOT increase cardiovascular risk.

But experts warn that reanalyzing a flawed study doesn't make it valid...and other studies DO suggest Avandia increases CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote